The role of Slfn4 in myocardial infarction: mechanisms and implications

Area of Science:

• Cardiovascular Biology
• Molecular Medicine
• Mitochondrial Dynamics

Background:

• Myocardial infarction (MI) causes significant cardiomyocyte death and limited therapeutic targets.
• Schlafen 4 (Slfn4) is a newly identified gene implicated in disease pathogenesis.
• Understanding Slfn4's role in MI is crucial for developing novel treatments.

Purpose of the Study:

• To investigate the role of Schlafen 4 (Slfn4) in myocardial infarction (MI).
• To determine if Slfn4 modulates mitophagy and mitochondrial fission in cardiac ischemic injury.
• To evaluate Slfn4 as a potential therapeutic target for MI.

Main Methods:

• Bioinformatic analysis of microarray data (GSE46395).
• Establishment of a myocardial infarction mouse model.
• In vitro studies using H9C2 cells under hypoxic conditions.
• Adeno-associated virus 9 (AAV9)-mediated shRNA for Slfn4 knockdown.
• Assessment of inflammatory markers, apoptosis, mitophagy (LC3 I/II, P62), and mitochondrial fission (DRP1).

Main Results:

• Slfn4 expression was significantly elevated in ischemic cardiac tissue and during MI.
• Slfn4 knockdown reduced cardiomyocyte apoptosis, inflammatory cell infiltration, and cardiac injury markers (ANP, BNP, cTnT, cTnI, IL-1β, TNF-α).
• Slfn4 inhibition promoted BNIP3-dependent mitophagy and suppressed DRP1-mediated mitochondrial fission, preserving mitochondrial quality control.

Conclusions:

• Slfn4 exacerbates MI-induced damage by inhibiting BNIP3-mediated mitophagy and promoting mitochondrial fission.
• Slfn4 knockdown demonstrates cardioprotective effects, enhancing cardiomyocyte survival and mitochondrial function.
• Modulating Slfn4 presents a promising therapeutic avenue for myocardial infarction treatment.